Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Design Therapeutics To Present Preclinical Data Highlighting The Potential Of Its GeneTAC Small Molecule, DT-216, For The Treatment Of Friedreich Ataxia At International Congress for Ataxia Research 2022 November 3

Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company's novel

DSGN